Question Bank › Selling into a customer's own emergency

Selling into a customer's own emergency

Calls Tested
496
Answered YES
12
Hit Rate
2.4%
rare by design

Alkermes plc (ALKS) — this company's answers

NO on the Q3 2018 call 2018-10-23 C
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes the company's offerings as relieving a pressing, costly problem the customer is already living with right now. The transcript covers VIVITROL, ARISTADA, ALKS 5461, ALKS 3831, BIIB098, and ALKS 4230. For VIVITROL, they discuss the opioid epidemic, legislation, and growth. They mention "opioid epidemic is a central theme" and "every community across the country affected." They talk about expanding availability of treatment. But is the customer's pain concrete and currently active? The customers are patients with opioid use disorder, and the product is a treatment. The pain is addiction, which is a pressing problem. However, management describes growth and policy initiatives, but does not explicitly say that buyers are acting under duress or that the purchase is relief from an active emergency. They talk about "improving continuity of care" and "access and awareness." It's more about building infrastructure and long-term growth. The urgency is not described as a current emergency that buyers are actively bleeding from. They mention "the opioid epidemic" but that's a societal issue, not a specific customer pain that is being relieved right now in a way that shows urgency in orders. They do say "we continue to see strong growth" and "27 states have demonstrated more than 25% growth year-over-year." That shows demand, but is it relief from an active problem? Possibly, but the description is more about policy and access, not about customers facing a deadline or penalty. For ARISTADA, they talk about launch of ARISTADA INITIO, and "value proposition resonating with physicians." They mention "real world utility across treatment settings, including hospitals and crisis stabilization units where many patients initiate long-acting treatment." That suggests patients in crisis, but the description is about product features and market share. They don't describe a specific pressing problem that customers are actively trying to solve with urgency. For ALKS 5461, they talk about the AdCom and data, but not about customer pain. For ALKS 3831, they talk about weight gain mitigation, but that's a benefit, not an active problem. For BIIB098, they talk about GI tolerability, but again, that's a benefit. For ALKS 4230, it's oncology, but they talk about clinical development, not current customer pain.

← Back to the full ALKS analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW — a shortage, failure, deadline, penalty, safety or compliance exposure, staffing gap, outage, backlog, spoilage, loss, or other pain the customer is actively bleeding from — such that the purchase functions as relief from an active problem rather than as an improvement, upgrade, or investment the customer could comfortably postpone? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation: the company's offering sits on the relief side of somebody else's live emergency, and buyers are acting accordingly today. Any genuine expression of this counts, and the form varies widely across industries. For example — management describing customers who cannot get something they need and are turning to this company to fill the gap; customers facing a deadline, mandate, court order, regulatory finding, audit, or contractual penalty that this company's product or service resolves; customers whose own operations are failing, breaking down, running short, running late, or losing money every day the problem persists, and who are buying to stop the loss; customers who cannot hire, cannot deliver, cannot produce, cannot comply, or cannot serve their own customers without what this company provides; buyers whose alternative to purchasing is an outcome plainly worse and more expensive than the price being charged; or management explaining that the spending decision is being made under duress rather than out of choice, and pointing to how that shows up in real orders, urgency, willingness to pay, or the kinds of conversations they are having now. Two things should come through in management's own voice. First, the customer's pain must be CONCRETE AND CURRENTLY ACTIVE — something the buyer is dealing with today, described specifically enough that one can see what goes wrong for the customer if nothing is bought — not a general claim that the product delivers value, saves money, or improves efficiency. Second, management must present this dynamic as ALREADY VISIBLE IN THE BUSINESS NOW — in orders, demand, urgency, pricing, or customer behavior in the recent period — rather than as a reason the market should eventually be large. Answer NO if the offering is described mainly in terms of benefits, savings, productivity, better performance, or attractive returns for the customer, however compelling — that is discretionary value, not relief from an active problem. NO if the pain described belongs to the company itself rather than to its customers. NO if the customer problem is generic or abstract ("customers face cost pressure," "the industry needs to modernize," "digital transformation is a priority"). NO if the urgency is only anticipated, forecast, or expected to emerge from some future rule, cycle, or condition not yet in force. NO if the buying pressure is attributed to a brief disruption management expects to pass and is not treating as characteristic of its market. NO if the only evidence is one isolated customer anecdote with no sense of a broader pattern. NO if management merely asserts that its product is essential, mission-critical, or non-discretionary without describing what the customer is actually up against. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
CEIX CONSOL Energy Inc. Q4 2022 2023-02-07 B
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
TENB Tenable Holdings, Inc. Q2 2021 2021-07-27 A
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
DHX DHI Group, Inc. Q2 2017 2017-07-28 D
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
VRNS Varonis Systems, Inc. Q2 2016 2016-08-09 B+

How the model reasoned

CEIX · Q4 2022 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES The transcript shows management describing customers buying coal to relieve an active shortage problem they are already facing. Key points include persistent coal supply shortages driving pricing, customers with low inventories (less than 20 days heading into winter), and spot needs in the back-half of the year. They also note Europe potentially relying on LNG after Russian gas depletes, and the supply of high-Btu coals still being constrained with demand remaining strong. This is presented as current market conditions visible in recent sales, pricing, and contracted volumes, not just a future improvement.
TENB · Q2 2021 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES Management describes customers facing active, ongoing cyber threats, ransomware attacks, high-profile breaches (e.g., Colonial Pipeline, Microsoft), and resulting business outages or disruptions that are driving immediate adoption of Tenable's solutions for continuous visibility, risk assessment, and prevention. This is framed as a current, pressing issue elevating discussions at the Board level and prompting purchases now, rather than future or optional improvements.
MITK · Q4 2017 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES Management describes the Equifax breach (earlier this year) as actively accelerating a "rapidly growing global problem" of verifying identity in a remote digital world, with enterprises turning to Mitek to "augment or replace traditional verification methods" because the Social Security number is "now widely breached" and "has run its race," making traditional methods "unsafe" and leading to fraud/identity theft.

More from the question bank

Analysts still asking about the old story whCenter of attention has moved to the newest Stale terms, scheduled resetLeaning into the stormManagement is playing referee between competTrajectory bent upward recently, and managemAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.